Seeking adults with Advanced or Metastatic Cancer
At the National Cancer Institute (NCI), Dr. James Gulley, M.D., Ph.D., and his team of researchers are dedicated to advancing cancer treatment through research. They are enrolling volunteers in a new clinical research study focusing on atezolizumab, an FDA-approved immunotherapy, designed to help the immune system fight cancer. In this study, the use of the drug is investigational as it aims to reduce the dose and/or frequency of atezolizumab to maintain effectiveness while potentially reducing side effects.
About the Study
During this study, we will track atezolizumab levels in the blood and adjust infusion schedules accordingly. The goal is to determine if patients can receive lower doses or less frequent infusions without compromising treatment effectiveness. Duration of the study may last for up to 2 years.
Who Can Join?
Researchers are seeking individuals who have cancer that has spread locally or to other organs and who are recommended to receive atezolizumab alone or in combination with other FDA-approved treatments.
What to Expect
- Screening tests to confirm eligibility to include tumor pathology results or collection of tumor tissue
- Bloodtests and imaging scans
- Atezolizumab infusions
- Visits to the NIH Clinical Center Outpatient Clinic for regular checkups and monitoring
- Duration of the study is up to 2 years
The NIH Clinical Center, America's research hospital, is located in Bethesda, MD, and is accessible by the Metro Red Line (Medical Center stop).
For More Information, Contact
NIH Clinical Center Office of Patient Recruitment
833-JOIN-NIH
TTY users dial 7-1-1
Email: ccopr@nih.gov
Or go online
Refer to NIH study # 001559-C
Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)